Name | Number of supported studies | Average coverage | |
---|---|---|---|
conventional dendritic cell | 24 studies | 46% ± 17% | |
mast cell | 18 studies | 30% ± 8% | |
dendritic cell | 15 studies | 42% ± 15% | |
plasmacytoid dendritic cell | 11 studies | 38% ± 15% | |
Langerhans cell | 3 studies | 54% ± 29% | |
monocyte-derived dendritic cell | 3 studies | 62% ± 28% | |
myeloid cell | 3 studies | 22% ± 4% | |
megakaryocyte-erythroid progenitor cell | 3 studies | 64% ± 20% | |
hematopoietic stem cell | 3 studies | 24% ± 3% |
Insufficient scRNA-seq data for expression of FCER1A at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 70% | 102.85 | 172 / 245 | 84% | 7.69 | 420 / 502 |
lung | 84% | 182.35 | 484 / 578 | 64% | 11.14 | 734 / 1155 |
breast | 59% | 96.33 | 270 / 459 | 71% | 9.42 | 793 / 1118 |
thymus | 47% | 54.27 | 305 / 653 | 79% | 15.01 | 478 / 605 |
esophagus | 82% | 172.54 | 1185 / 1445 | 38% | 3.05 | 70 / 183 |
kidney | 38% | 70.97 | 34 / 89 | 78% | 11.39 | 704 / 901 |
bladder | 67% | 106.90 | 14 / 21 | 44% | 3.96 | 221 / 504 |
skin | 72% | 364.85 | 1299 / 1809 | 29% | 2.34 | 138 / 472 |
intestine | 67% | 90.90 | 652 / 966 | 32% | 1.97 | 169 / 527 |
uterus | 46% | 55.38 | 79 / 170 | 47% | 5.46 | 215 / 459 |
pancreas | 8% | 5.19 | 25 / 328 | 79% | 12.15 | 141 / 178 |
tonsil | 0% | 0 | 0 / 0 | 73% | 8.16 | 33 / 45 |
adrenal gland | 21% | 14.27 | 53 / 258 | 47% | 4.50 | 108 / 230 |
stomach | 37% | 35.36 | 132 / 359 | 30% | 2.30 | 86 / 286 |
adipose | 62% | 124.50 | 748 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 60% | 119.34 | 807 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 46% | 135.58 | 431 / 929 | 0% | 0 | 0 / 0 |
liver | 14% | 9.72 | 32 / 226 | 31% | 2.66 | 127 / 406 |
ovary | 7% | 4.63 | 13 / 180 | 31% | 2.30 | 133 / 430 |
brain | 5% | 3.26 | 129 / 2642 | 28% | 2.07 | 195 / 705 |
spleen | 32% | 34.10 | 77 / 241 | 0% | 0 | 0 / 0 |
heart | 19% | 14.74 | 163 / 861 | 0% | 0 | 0 / 0 |
muscle | 8% | 4.96 | 63 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 4% | 0.26 | 3 / 80 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.07 | 1 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0043303 | Biological process | mast cell degranulation |
GO_0042092 | Biological process | type 2 immune response |
GO_0043308 | Biological process | eosinophil degranulation |
GO_0016068 | Biological process | type I hypersensitivity |
GO_0038095 | Biological process | Fc-epsilon receptor signaling pathway |
GO_0016064 | Biological process | immunoglobulin mediated immune response |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0009986 | Cellular component | cell surface |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0019768 | Molecular function | high-affinity IgE receptor activity |
GO_0005515 | Molecular function | protein binding |
GO_0019863 | Molecular function | IgE binding |
Gene name | FCER1A |
Protein name | Fc of IgE, high affinity I, receptor for alpha polypeptide Fc epsilon receptor Ia High affinity immunoglobulin epsilon receptor subunit alpha (Fc-epsilon RI-alpha) (FcERI) (IgE Fc receptor subunit alpha) |
Synonyms | FCE1A |
Description | FUNCTION: High-affinity receptor for immunoglobulin epsilon/IgE. Mediates IgE effector functions in myeloid cells. Upon IgE binding and antigen/allergen cross-linking initiates signaling pathways that lead to myeloid cell activation and differentiation. On mast cells, basophils and eosinophils stimulates the secretion of vasoactive amines, lipid mediators and cytokines that contribute to inflammatory response, tissue remodeling and cytotoxicity against microbes. Triggers the immediate hypersensitivity response to allergens as a host defense mechanism against helminth parasites, pathogenic bacteria and venom toxicity. When dysregulated, it can elicit harmful life-threatening allergic and anaphylactic reactions. . |
Accessions | ENST00000709173.1 ENST00000368114.1 Q6GU38 ENST00000693622.1 ENST00000709171.1 P12319 ENST00000368115.5 E9PRN1 |